Combination therapy for multiple sclerosis: The treatment strategy of the future?

CNS Drugs

Volumn 18, Issue 12, 2004, Pages 777-792

  Weinstock Guttman, Bianca ^a,b   Bakshi, Rohit ^c  

^a JACOBS NEUROLOGICAL INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; AZATHIOPRINE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA1A INTERFERON; CORTICOSTEROID; CYANOCOBALAMIN; CYCLOPHOSPHAMIDE; DACLIZUMAB; FOLINIC ACID; GLATIRAMER; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; INTERFERON BETA SERINE; LOFEPRAMINE; MATRIX METALLOPROTEINASE INHIBITOR; METHOTREXATE; METHYLPREDNISOLONE; MINOCYCLINE; MITOXANTRONE; NATALIZUMAB; PENTOXIFYLLINE; PHENYLALANINE; PREDNISONE; SALBUTAMOL; STATINE DERIVATIVE; VALACICLOVIR;

ALOPECIA; AMENORRHEA; AUTOIMMUNE DISEASE; BONE MARROW SUPPRESSION; CARDIOTOXICITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEMYELINATING DISEASE; DIET SUPPLEMENTATION; DISEASE COURSE; DRUG MECHANISM; HEADACHE; HEMORRHAGIC CYSTITIS; HUMAN; IMMUNOMODULATION; LEUKOPENIA; LIVER TOXICITY; LOW FAT DIET; META ANALYSIS; MULTIPLE SCLEROSIS; MYOCARDITIS; NAUSEA; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SKIN MANIFESTATION; SYSTEMATIC REVIEW; URINARY TRACT INFECTION;

ADJUVANTS, IMMUNOLOGIC; ANTIOXIDANTS; ANTIVIRAL AGENTS; COMBINED MODALITY THERAPY; DEMYELINATING AUTOIMMUNE DISEASES, CNS; DRUG THERAPY, COMBINATION; HORMONES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; MULTIPLE SCLEROSIS;

EID: 6944232052     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200418120-00003     Document Type: Review

References (85)

1. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996; 46: 907-11
2. Lucchinetti C, Bruck W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47: 707-17
3. Lucchinetti CF, Mandler RN, McGavern D, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002; 125: 1450-61
4. Barnett MH, Prineas JW. Relapsing remitting multiple sclerosis: pathology of the newly forming lesion. Brain 2004; 55: 458-68
5. IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double blind, placebo-controlled trial. Neurology 1993; 43 (4): 655-61
6. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285-94
7. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomized double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498-504
8. Weinstock-Guttman B, Ransohoff RM, Kinkel RP, et al. The interferons: biological effects mechanisms of action, and use in multiple sclerosis. Ann Neurol 1995; 37: 7-15
9. Yong VW, Chabot S, Stuve O, et al. Interferon beta in the treatment of multiple sclerosis: mechanism of action. Neurology 1998; 51: 682-9
10. European Study Group on Interferon β-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491-7
11. Secondary Progressive Efficacy Clinical trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of recombinant interferon beta-1a in secondary progressive MS: clinical results. Neurology 2001; 56: 1496-504
12. Goodkin DE, the North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: clinical and MRI results of a 3-year randomized controlled trial [abstract]. Late Breaking News. Presented at the 52nd annual meeting of the American Academy of Neurology; 2000 Apr 29-May 6, San Diego
13. Cohen JA, Cutter GR, Fischer JS, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 2002; 59: 679-87
14. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995; 45: 1268-76
15. Chen M, Gran B, Costello K, et al. Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS. Mult Scler 2001; 7: 209-19
16. Dhib-Jalbut S. Sustained immunological effects of glatiramer acetate in patients with multiple sclerosis treated for over 6 years. J Neurol Sci 2002; 201: 71-7
17. Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging: measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 2001; 49: 290-7
18. Calabresi PA, Stone LA, Bash CN, et al. Interferon beta results in immediate reduction of contrast-enhanced MRI lesions in multiple sclerosis patients followed by weekly MRI. Neurology 1997; 48: 1446-8
19. Hartung HP, Gonsette R, Konig N, and the MIMS-Study Group, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomized, multicenter trial. Lancet 2002; 360: 2018-25
20. Leary SM, Miller DH, Stevenson VL, et al. Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology 2003; 60: 44-51
21. Kita M, Cohen JA, Rox R, et al. A phase II trial of mitoxantrone in patients with primary progressive MS [abstract]. Neurology 2004; 62: A99
22. Lublin F, Cutter G, Elfont R, et al. A trial to assess the safety of combining therapy with interferon beta-1a and glatiramer acetate in patients with relapsing MS [abstract]. Neurology 2001; 56 Suppl. 3: A148
23. Moreau T, Blanc S, Riche G, et al. ERAZISMUS: Early Azathioprine versus Beta-Interferon treatment in Multiple Sclerosis: results of a pilot study [abstract]. The 9th Annual Meeting of the European Neurological Society; Milan 1999 Jun 5-9, 143
24. Havrdova E, Ticha V, Novakova I, et al. Intramuscular interferon beta-1a in combination with azathioprine and low-dose steroids for relapsing-remitting multiple sclerosis: design and preliminary results of a two-year double-blind, randomized, placebo-controlled study [abstract]. Neurology 2001; 56 Suppl. 3: A356
25. Fernandez O, Guerro M, Mayorga C, et al. Combination therapy with interferon beta-1b and azathioprine in secondary progressive MS: a 2 year pilot study. J Neurol 2002; 249: 1058-62
26. Rowe VD, Wang D, John HA, et al. Rescue therapy with high dose intravenous methotrexate in MS patients worsening despite Avonex therapy [abstract]. Neurology 2003; 60 Suppl. 1: A149
27. Bielekova B, Reichert-Scrivner S, Wuerfel J, et al. Combination therapy of MS patients with incomplete response to interferon-beta with humanized antibody against the interleukin-2 receptor alpha chain [abstract]. Mult Scler 2002; 8 Suppl. 1: S4
28. Smith DR, Weinstock-Guttman B, Cohen JA, et al. Blinded randomized trial of pulse cyclophosphamide in IFN beta resistant active MS [abstract]. Neurology 2003; 60 Suppl. 1: A84
29. Jeffrey DR, Durden DD, Burdette JH. Pilot trial of IFN beta-1b and mitoxantrone in multiple sclerosis using monthly gadolinium enhanced MRI [abstract]. Neurology 2001; 56 Suppl. 3: A353
30. Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS; the EVIDENCE Trial. Neurology 2002; 359: 1453-60
31. Durelli L, Verdun E, Barbero P, et al. Every other day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis; results of a 2-year prospective randomized multicenter study (INCOMIN). Lancet 2002; 359: 1453-60
32. IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first 3 years. Neurology 1996; 47: 889-94
33. The PRISMS Study Group and the University of British Columbia MS/MR1 Analysis Group. PRISMS-4: long-term efficacy of interferon beta-1a in relapsing MS. Neurology 2001; 56: 1628-36
34. Pachner AR. Anti-IFNB antibodies in IFNB-treated MS patients. Neurology 2003; 61 Suppl. 5: S1-5
35. Sorensen PS, Ross C, Clemmesen KM, et al. Clinical importance of neutralizing antibodies against interferon beta in patients with relapsing remitting multiple sclerosis. Lancet 2003; 302: 1184-91
36. Milo R, Panitch H. Additive effects of copolymer-1 and interferon beta-1b on the immune response to myelin basic protein. J Neuroimmunol 1995; 61: 185-93
37. Brod SA, Lindsey JW, Wolinsky JS. Combination therapy with glatiramer acetate (copolymer-1) and a type 1 interferon (IFN-alpha) does not improve experimental autoimmune encephalomyelitis. Ann Neurol 2000; 47: 127-31
38. Zang Y, Hong J, Robinson R, et al. Immune regulatory properties and interactions of copolymer 1 and beta-interferon 1a in MS. J Neuroimmunol 2003; 137 (1-2): 144-53
39. Yudkin PL, Ellison GW, Ghezzi A, et al. Overview of azathioprine treatment in multiple sclerosis. Lancet 1991; 38: 1051-5
40. Goodkin DE, Rudick RA, VanderBrug Medendorp S, et al. Low dose (7.5mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 1995; 37: 30-40
41. Goodkin DE, Rudick RA, VanderBrug Medendorp S. Low-dose oral methotrexate in chronic progressive multiple sclerosis: analysis of serial MRIs. Neurology 1996; 47: 1153-7
42. Calabresi PA, Wilterdink JL, Rogg JM, et al. An open-label trial of combination therapy with interferon beta-1a and oral methotrexate in MS. Neurology 2002; 58: 314-7
43. Rowe VD, Dressman LA, Wang D, et al. High dose intravenous methotrexate in MS patients worsening despite Avonex therapy: final results [abstract]. Neurology 2004; 62: A260
44. Durelli L, Cocito D, Riccio A. High dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunologic correlations. Neurology 1986; 36: 238-43
45. Andersson PB, Goodkin DE. Glucocorticosteroid therapy for multiple sclerosis: a critical review. J Neurol Sci 1998; 160: 16-25
46. Barnes D, Hughes RAC, Morris R, et al. Randomized trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet 1997; 349: 902-6
47. Beck RW, Cleary PA, Trabe J, et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med 1993; 329: 1764-9
48. Goodkin DE, Kinkel RP, Weinstock-Guttman B, et al. A phase II study of IV methylprednisolone in secondary-progressive multiple sclerosis. Neurology 1998; 51: 239-45
49. Zivadinov R, Rudick RA, De Masi R, et al. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 2001; 57: 1239-47
50. Salama HH, Kolar OJ, Zang YC, et al. Effects of combination therapy of beta-interferon 1a and prednisone on serum immunologic markers in patients with multiple sclerosis. Mult Scler 2003; 9: 28-31
51. Fazekas F, Deisenhammer F, Strasser FS, et al. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet 1997; 349: 589-93
52. Sorensen PS, Wanscher B, Jensen CV, et al. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 1998; 50: 1273-81
53. Archelos JJ, Previtali SC, Hartung HP. The role of integrins in immune-mediated diseases of the nervous system. Trends Neurosci 1999; 22: 30-8
54. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348: 15-23
55. Vollmer TL, Phillips JT, Goodman AD, et al. An open-label safety and drug interaction study of natalizumab in combination with Interferon beta (Avonex. Mult Scler. In press 2004
56. Rosenberg GA. Matrix metalloproteinases and neuroinflammation in multiple sclerosis. Neuroscientist 2002; 8: 586-95
57. Nelissen I, Martens E, Van Den Steen PE, et al. Gelatinase B/matrix metalloproteinase-9 cleaves interferon-β and is a target for immunotherapy. Brain 2003; 126: 1371-81
58. Brundula V, Rewcastle NB, Metz LM, et al. Targeting leukocyte MMPs and transmigration; Minocycline as a potential therapy for multiple sclerosis. Brain 2002; 125: 1297-308
59. Popovic N, Schubart A, Goetz BD, et al. Inhibition of autoimmune encephalomyelitis by a tetracycline. Ann Neurol 2002; 51: 215-23
60. Weber F, Polak T, Gunther A, et al. Synergistic immunomodulatory effects of interferon-beta1b and the phosphodiesterase inhibitor pentoxifylline in patients with relapsing-remitting multiple sclerosis. Ann Neurol 1998; 44: 27-34
61. Makhlouf K, Weiner HL, Khoury SJ. Potential of beta-2-adrenoceptor agonist as add-on therapy for multiple sclerosis: focus on salbutamol (albuterol). CNS Drugs 2002; 16: 1-8
62. Hauser SL, Dawson DM, Lehrich JR, et al. Intensive immunosuppression in progressive multiple sclerosis; a randomized, three arm study of high-dose intravenous cyclophosphamide, plasma exchange and ACTH. N Engl J Med 1983; 308: 173-80
63. Weiner HL, Mackin GA, Orav EJ, et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology 1993; 43: 910-8
64. The Canadian Cooperative Multiple Sclerosis Group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 1991; 337: 441-6
65. Weinstock-Guttman B, Kinkel RP, Cohen JA, et al. Treatment of fulminant multiple sclerosis with intravenous cyclophosphamide. Neurologist 1997; 3: 178-85
66. Gobbini MI, Smith ME, Richert ND, et al. Effect of open-label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis. J Neuroimmunol 1999; 99: 142-9
67. Kaufman M, Norton HJ, Sonnefeld G. A randomized controlled safety trial of IFN beta 1-a and oral cyclophosphamide in MS. Int J MS Care 2002; 4 (4): 174-82
68. Bieber AJ, Kerr S, Rodriguez M. Efficient central nervous system remyelination requires T cells. Ann Neurol 2003; 53: 680-4
69. Wade DT, Young CA, Chaudhuri KR, et al. A randomized placebo controlled exploratory study of Vit B12, lofepramine and L-phenylalanine (the "Cari Loder regime") in the treatment of MS. J Neurol Neurosurg Psychiatry 2002; 73: 246-9
70. Puri BK, Bydder GM, Chaudhuri KR, et al. MRI changes in MS following treatment with lofepramine and L-phenylalanine. Neuroreport 2001; 12: 1821-4
71. Calder PC. Fat chance of immunomodulation. Trends Immunol Today 1998; 19: 244-7
72. Thies F, Nebe-von-Caron G, Powell JR, et al. Dietary supplementation with gamma linolenic acid or fish oil decreases T-lymphocyte proliferation in healthy older humans. J Nutr 2001; 131 (7): 1918-27
73. James MJ, Gibson RA, Cleland LG. Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr 2000; 71 (1): 343-348S
74. Swank RL, Dugan BB. Effect of low saturated fat diet in early and late cases of multiple sclerosis. Lancet 1990; 336: 37-9
75. Dworkin RH, Bates D, Millar JHD, et al. Linoleic acid and multiple sclerosis: a reanalysis of three double-blind trials. Neurology 1984; 34: 1441-5
76. Weinstock-Guttman B, Baier M, Feichter J, et al. A randomized study of low fat diet with omega-3 fatty acids supplementation in patients with RRMS [abstract]. Neurology 2003; 60 Suppl. 1: A151
77. Swanborg RH, Whittum-Hudson JA, Hudson AP. Human herpes virus 6 and chlamydia pneumoniae as etiologic agents in MS: a critical review. Microbes Infect 2002; 4: 1327-33
78. Lycke J, Svennerholm B, Hjelmquist E, et al. Acyclovir treatment of RRMS: a randomized, placebo-controlled, double-blind study. J Neurol 1996; 243: 214-24
79. Liu B, Gao H. Role of nitric oxide in inflammation-mediated neurodegeneration. Ann N Y Acad Sci 2002; 962: 318-31
80. Bakshi R, Benedict RHB, Bermel RA, et al. T2 hypointensity in the deep gray matter of patients with multiple sclerosis: a quantitative magnetic resonance imaging study. Arch Neurol 2002; 59: 62-8
81. Sicotte NL, Liva SM, Klutch R, et al. Treatment of multiple sclerosis with pregnancy hormone estriol. Ann Neurol 2002; 52: 421-8
82. Stuve O, Prod'homme T, Slavin A, et al. Statins and their potential targets in multiple sclerosis therapy. Expert Opin Ther Targets 2003; 7: 613-22
83. Stuve O, Youssef S, Steinman L, et al. Statins as potential therapeutic agents in neuroinflammatory disorders. Curr Opin Neurol 2003; 16: 393-401
84. Youssef S, Stuve O, Patarroyo JC, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002; 420: 39-40
85. Colman D, Lubelzki C, Reingold S. Multiple paths, towards repair in MS. Trends Neurosci 2003; 26: 59-61